Lineage Cell Therapeutics, Inc. Stock Issued During Period, Value, Stock Options Exercised
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- Lineage Cell Therapeutics, Inc. stock issued during period, value, stock options exercised for the quarter ending 2026-06-30 was $6.00K.
- Lineage Cell Therapeutics, Inc. stock issued during period, value, stock options exercised for the quarter ending 2026-03-31 was $227.00K.
- Lineage Cell Therapeutics, Inc. stock issued during period, value, stock options exercised for the quarter ending 2025-12-31 was $604.00K.
- Lineage Cell Therapeutics, Inc. stock issued during period, value, stock options exercised for the quarter ending 2025-09-30 was $646.00K, a 6360.00% increase year-over-year.
- Lineage Cell Therapeutics, Inc. stock issued during period, value, stock options exercised for fiscal 2025 was $1.25M, a 445.85% increase from fiscal 2024.
- Lineage Cell Therapeutics, Inc. stock issued during period, value, stock options exercised for fiscal 2024 was $229.00K, a 308.93% increase from fiscal 2023.
- Lineage Cell Therapeutics, Inc. stock issued during period, value, stock options exercised for fiscal 2023 was $56.00K, a 88.57% decline from fiscal 2022.
- Lineage Cell Therapeutics, Inc. stock issued during period, value, stock options exercised for fiscal 2022 was $490.00K.
| Period end | Stock Issued During Period, Value, Stock Options Exercised 3 month | Stock Issued During Period, Value, Stock Options Exercised 12 month |
|---|---|---|
| 2026-06-30 | $6.00K 10-Q · filed 2026-08-06 | $1.48M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $227.00K 10-Q · filed 2026-05-12 | |
| 2025-12-31 | $604.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | $1.25M 10-K · filed 2026-03-05 |
| 2025-09-30 | $646.00K 10-Q · filed 2025-11-06 | |
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | $229.00K 10-K · filed 2026-03-05 |
| 2024-09-30 | $10.00K 10-Q · filed 2025-11-06 | $230.00K derived: sum of 4 quarters · filed 2025-11-06 |
| 2024-06-30 | $56.00K 10-Q · filed 2025-08-12 | $228.00K derived: sum of 4 quarters · filed 2025-08-12 |
| 2024-03-31 | $163.00K 10-Q · filed 2025-05-13 | $194.00K derived: sum of 4 quarters · filed 2025-05-13 |
| 2023-12-31 | $1.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-10 | $56.00K 10-K · filed 2025-03-10 |
| 2023-09-30 | $8.00K 10-Q · filed 2024-11-14 | |
| 2023-06-30 | $22.00K 10-Q · filed 2024-08-08 | |
| 2023-03-31 | $25.00K 10-Q · filed 2024-05-09 | |
| 2022-12-31 | $490.00K 10-K · filed 2024-03-07 | |
| 2022-09-30 | $118.00K 10-Q · filed 2023-11-09 | |
| 2022-06-30 | $10.00K 10-Q · filed 2023-11-09 | |
| 2022-03-31 | $189.00K 10-Q · filed 2023-11-09 | |
| 2021-09-30 | $485.00K 10-Q · filed 2022-11-10 | |
| 2021-06-30 | $4.03M 10-Q · filed 2022-11-10 | |
| 2021-03-31 | $1.75M 10-Q · filed 2022-11-10 | |
| 2017-12-31 | $25.00K 10-K · filed 2019-03-14 | |
| 2015-12-31 | $621.00K 10-K · filed 2018-03-15 | |
| 2014-12-31 | $219.30K derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-16 | $1.19M 10-K · filed 2017-03-16 |
| 2013-12-31 | $46.00K derived: 10-K 12 month − 10-Q 9 month · filed 2016-03-15 | $46.00K 10-K · filed 2016-03-15 |
| 2012-12-31 | $286.55K 10-K · filed 2015-03-11 | |
| 2011-12-31 | $251.98K 10-K · filed 2014-03-17 | |
| 2010-12-31 | $855.98K 10-K · filed 2013-03-18 | |
| 2009-12-31 | $848.45K 10-K · filed 2012-03-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aligos Therapeutics, Inc. (ALGS) | United States | $0.238B | -0.47 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| Protalix BioTherapeutics, Inc. (PLX) | $0.221B | 9.87 | |
| ANAVEX LIFE SCIENCES CORP. (AVXL) | United States | $0.218B | -18.37 |
| Alector, Inc. (ALEC) | United States | $0.213B | -1.90 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Compass Therapeutics, Inc. (CMPX) | United States | $0.204B | -5.35 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |